INNATE PHARMA SA (IDD.DE) Stock Price & Overview
FRA:IDD • FR0010331421
Current stock price
The current stock price of IDD.DE is 1.424 EUR. Today IDD.DE is up by 19.26%.
IDD.DE Key Statistics
- Market Cap
- 133.614M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.80
- Dividend Yield
- N/A
IDD.DE Stock Performance
IDD.DE Stock Chart
IDD.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IDD.DE.
IDD.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IDD.DE. IDD.DE may be in some trouble as it scores bad on both profitability and health.
IDD.DE Earnings
On April 1, 2026 IDD.DE reported an EPS of -0.55 and a revenue of 2.79M. The company missed EPS expectations (-353.8% surprise) and beat revenue expectations (25.56% surprise).
IDD.DE Forecast & Estimates
8 analysts have analysed IDD.DE and the average price target is 5.82 EUR. This implies a price increase of 308.37% is expected in the next year compared to the current price of 1.424.
For the next year, analysts expect an EPS growth of 13.33% and a revenue growth -1.93% for IDD.DE
IDD.DE Groups
Sector & Classification
IDD.DE Financial Highlights
Over the last trailing twelve months IDD.DE reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS decreased by -30.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IDD.DE Ownership
IDD.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.71 | 42.625B | ||
| 1AE | ARGENX SE | 28.77 | 42.6B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.126B | ||
| ABVX | ABIVAX SA | N/A | 7.766B | ||
| 2X1 | ABIVAX SA | N/A | 7.747B | ||
| GLPG | GALAPAGOS NV | N/A | 1.629B | ||
| GXE | GALAPAGOS NV | N/A | 1.628B | ||
| NANO | NANOBIOTIX | N/A | 1.392B | ||
| PHARM | PHARMING GROUP NV | 46.9 | 1.025B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.021B | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| IVA | INVENTIVA SA | N/A | 934.695M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About IDD.DE
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
IPO: 2006-10-31
INNATE PHARMA SA
117 avenue de Luminy, Bp 30191
Marseille PACA FR
Employees: 163
Phone: 33430303030
INNATE PHARMA SA / IDD.DE FAQ
Can you describe the business of INNATE PHARMA SA?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Can you provide the latest stock price for INNATE PHARMA SA?
The current stock price of IDD.DE is 1.424 EUR. The price increased by 19.26% in the last trading session.
Does IDD stock pay dividends?
IDD.DE does not pay a dividend.
How is the ChartMill rating for INNATE PHARMA SA?
IDD.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of IDD stock?
INNATE PHARMA SA (IDD.DE) has a market capitalization of 133.61M EUR. This makes IDD.DE a Micro Cap stock.